Point of View on Early Triple Negative
|
|
- Denis Fitzgerald
- 5 years ago
- Views:
Transcription
1 Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini
2 Outline Neoadjuvant Setting IPSY-2 GeparSepto Adjuvant Setting EBCTCG Meta-analysis NSABP-B47 Fertility preservation and Meta-analysis POSTER & ABSTRACT or ONGOING Studies
3 Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC): pcr correlates with long-term oucome Cortazar P et al, The Lancet 2014
4 Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC): pcr correlates with long-term oucome pcr Rates by Tumor Subtypes Cortazar P et al, The Lancet 2014
5 Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC): pcr correlates with long-term oucome Cortazar P et al, The Lancet 2014
6 Neoadjuvant Model as a Platform to test Emerging Therapies/Concepts Accelerated path for drug approval Additive Model to improves DFS/OS Identify subsets for therapy de-escalation Subtractive model to enrich for patients expected to have excellent RFS/OS & reduce toxicity Identify subsets for therapy escalation Additive model to address residual risk
7 Yee et al. SABCS 2017 General Session 3
8 I-SPY 2 Trial pcr Distribution by Subtype EFS Dataset pcr distribution by subtype Evaluable population: (35%) pcr, 487 (65%) non-pcr Median Follow-up: 2.7 yrs ( ) 126 EFS events, 109 DRFS events 12 patients did not go to surgery Considered non-pcr per protocol Yee et al. SABCS 2017 General Session 3
9 I-SPY 2 Trial Results pcr is a highly significant predictor of EFS and DRFS EFS OVERALL DRFS Yee et al. SABCS 2017 General Session 3
10 I-SPY 2 Trial Results pcr is predictive of EFS and DRFS in TNBC EFS DRFS Yee et al. SABCS 2017 General Session 3
11 I-SPY 2 Trial Conclusions pcr is a strong predictor of EFS and DRFS in the setting of a multiple agent platform trial that includes: Standards for eligibility High risk for early recurrence (MP low risk, HR+HER2 excluded) Exclusion of metastatic disease All chemotherapy given before pcr determination Standards for pathologist assessment and multidisciplinary identification (surgeons, radiologists, pathologists) Long term follow-up of patients over time (correlation of early, intermediate, and late endpoints) pcr is equally predictive across all tumor subsets pcr as an endpoint enables rapid evaluation of novel therapy combinations and can accelerate the identification of effective and poentially less toxic regimens Yee et al. SABCS 2017 General Session 3
12 I-SPY 2 Trial The Future of I-SPY 2 Achieving pcr through any therapy for any subtype is a sufficient endpoint Develop minimally invasive techiniques (MRI and Biopsy) to identify pcr prior to definitive surgery Validate robust MRI and tissue predictors of pcr Descalate toxic therapy (AC) if pcr obtained early Re-assign patients to new therapies if pcr is not predicted Validate robust MRI and tissue predictors of non-pcr Assign new therapies based on molecular profiling of tumor and link to investigational agents Yee et al. SABCS 2017 General Session 3
13 Survival Analysis of the Prospectively Randomized Phase III GeparSepto Trial comparing Neoadjuvant Chemotherapy with weekly Nab-Paclitaxel with solvent-based Paclitaxel Followed by Anthracycline/Cyclophosphamide for patients with Early Breast Cancer GBG69 Study Design Main Eligibility Criteria Unilateral or bilateral primary breast cancer Stages: ct2 ct4a.d ct1c and additional high risk: o cn+ or pn SLN+ or ER ad PgR neg or Ki67 >20% or HER2 positive Study Endpoints Primary Endpoint: - pcr Rate (ypt0 ypn0) Secondary Eficacy endpoints (overall and according to stratified subpopulations) - DFS, DDFS, OS Schneeweiss et al. SABCS 2017 General Session 3
14 GeparSepto Trial pcr Analysis Paclitaxel Nab-Paclitaxel TN pcr 26% 48% pcr 22% Untch et al. Lancet Oncol 2016
15 GeparSepto Trial Disease Free Survival Analysis in Overall Population Disease Free Survival at median Follow-up of 49 months Schneeweiss et al. SABCS 2017 General Session 3
16 GeparSepto Trial Disease Free Survival Analysis according to Stratified Subpopulations Disease Free Survival at median Follow-up of 49 months Schneeweiss et al. SABCS 2017 General Session 3
17 GeparSepto Trial Exploratory Analysis Surrogate Value of pcr in the exploratory analysis Schneeweiss et al. SABCS 2017 General Session 3
18 GeparSepto Trial Conclusions GepardSepto demonstrates a significantly improved DFS when patients received nab-paclitaxel instead of paclitaxel (HR=0.69, 95% CI [ ; log rank p=0.0044] A similar treatment effect was observed for patients with TNBC and HR+/HER2- tumors The interaction with Ki67 suggests that nab-paclitaxel generates a long term benefit in particular in tumors with lower proliferation Irrespective of the treatment group, patients achieving a pcr had a significantly better DFS Patients without pcr have a significantly better DFS with nab-paclitaxel than paclitaxel Schneeweiss et al. SABCS 2017 General Session 3
19 Outline Neoadjuvant Setting IPSY-2 GeparSepto Adjuvant Setting EBCTCG Meta-analysis NSABP-B47 Fertility preservation and Meta-analysis POSTER & ABSTRACT or ONGOING Studies
20
21 EBCTCG meta-analysis Background Three ways to increase dose intensity (ie, the drug dose in mg/m² per week) 1. Use higher doses of drugs in each cycle 2. Reduce the interval between treatmen cycles 3. Give drugs sequentially rather than concurrently Norton L. Sem Oncol 1997
22 EBCTCG meta-analysis Pooled analysis of all 25 dose-dense and sequential trials Any Recurrence Breast Cancer Mortality Gray et al. SABCS 2017 General Session 1
23 EBCTCG meta-analysis Pooled Analysis: recurrence by ER Status ER - Negative ER - Positive Gray et al. SABCS 2017 General Session 1
24 EBCTCG meta-analysis Conclusions Shortening the interval between cycles and sequential administration of anthracycline and taxane chemotherapy reduces recurrence and death from breast cancer Reductions in recurrence of about 15% were similar in ER positive and ER negative disease and did not differ significantly by any other tumour or patient characteristic No increase seen in death without recurrence (ovrerall or during chemotherapy Gray et al. SABCS 2017 General Session 1
25
26 B-47: Adjuvant Trastuzumab in HER2 Low Breast Cancer Background NSABP B-31 Study Details NSABP B-31 Central HER2 Assay Result AC Paclitaxel with o without trastuzumab HER2+ node-positive breast cancer Initial study entry criteria included FISH or IHC 3+ HER2 testing performed at local lab site A tissue speciment sent to NSABP for later testing Before amendment (Any lab) After amendment (qualified lab) Central HER2 FISH negative 103/529 (19.5%) 104/1266 (8.2%) Central IHC negative (0-2+) 122/528 (23.1%) 177/1259 (14.1%) Both negative 87/529 (16.4%) 87/1266 (6.8%) NSABP B-31: Central HER2 status performed as quality check after 529 patients enrolled Total Final 207/1795 (11.5%) 299/1787 (16.7%) 174/1795 (9.7%) Fehrenbacher et al. SABCS 2017 General Session 1
27 B-47: Adjuvant Trastuzumab in HER2 Low Breast Cancer Patients characteristics Fehrenbacher et al. SABCS 2017 General Session 1
28 B-47: Adjuvant Trastuzumab in HER2 Low Breast Cancer Results Invasive Disease Free Survival Fehrenbacher et al. SABCS 2017 General Session 1
29 B-47: Adjuvant Trastuzumab in HER2 Low Breast Cancer Conclusions The benefit of trastuzumab in central tested HER2-low patients identified retrospectively from 2 major adjuvant trials that used local testing for eligibility are not really explained and not confirmed in this study There is NO benefit with trastuzumab therapy in patients with FISH ratios <2.0 and IHC staining intensity of 1+ or 2+ Fehrenbacher et al. SABCS 2017 General Session 1
30
31 Pooled analysis of randomized trials investigating GnRHa as a strategy to preserve fertility during chemotherapy in EBC Study & Baseline characteristics Lambertini et al. SABCS 2017 General Session 1
32 Pooled analysis of randomized trials investigating GnRHa as a strategy to preserve fertility during chemotherapy in EBC Results Premature-Ovarian Insufficiency Rate OR* 0.38 (95% CI ) p<0.001 Meta-analysis approach 50% Study GnRHa Events/pts Control Events/pts OR (95% CI) 40% 30% 30.9% PROMISE-GIM6 16/148 POEMS/SWOG S0230 5/66 UCSF-led trial 3/26 40/133 15/69 2/ (0.15, 0.57) 0.33 (0.10, 1.14) 1.17 (0.14, 9.55) 20% 14.1% GBG-37 ZORO OPTION 6/28 21/95 13/29 41/ (0.14, 2.07) 0.41 (0.20, 0.81) 10% Overall (I =0%,p=0.73) 51/ / (0.25, 0.57) 0% GnRHa group n=363 Control group n= GnRHa better Control better *Odds ratio (OR) adjusted for age, estrogen receptor status, type and duration of chemotherapy administered
33 Pooled analysis of randomized trials investigating GnRHa as a strategy to preserve fertility during chemotherapy in EBC Results Post-Treatment Pregnancy Rate GnRHa Group: 37/359 (10.3%) vs. Control Group: 20/367 (5.5%) Meta-analysis approach IRR* 1.83 (95% CI ) p=0.030 Study GnRHa Events/pts Control Events/pts IRR (95% CI) Age distribution, years GnRHa group (n = 37) No. (%) 37 (100) 0 (0.0) Control group (n = 20) No. (%) 20 (100) 0 (0.0) PROMISE-GIM6 8/148 3/133 POEMS/SWOG S /105 12/113 OPTION 7/106 5/121 Overall (I =0%,p=0.85) 37/359 20/ (0.67, 9.50) 1.77 (0.87, 3.57) 1.54 (0.49, 4.85) 1.82 (1.05, 3.14) Estrogen receptor status Positive Negative 6 (16.2) 31 (83.8) 2 (10.0) 18 (90.0) Control better GnRHa better Lambertini et al. SABCS 2017 General Session 1
34 Pooled analysis of randomized trials investigating GnRHa as a strategy to preserve fertility during chemotherapy in EBC Conclusions Administration of GnRHa during chemotherapy was associated with a significant reduction in the risk of chemotherapy-induced POI A greater number of women in the GnRHa group had a post-treatment pregnancy Similar DFS and OS were observed between groups irrespective of the estrogen receptor status of the disease This strategy should be considered as an option to reduce the likelihood of chemotherapy induced POI and potentially improve future fertility in premenopausal early breast cancer patients undergoing (neo)adjuvant chemotherapy Lambertini et al. SABCS 2017 General Session 1
35 Outline Neoadjuvant Setting IPSY-2 GeparSepto Adjuvant Setting EBCTCG Meta-analysis NSABP-B47 Fertility preservation and Meta-analysis POSTER & ABSTRACT or ONGOING Studies
36 Older age Morante et al. SABCS 2017 Mina et al. SABCS 2017 Satram-Hoang et al. SABCS 2017
37 Mittendorf et al. SABCS 2017
38
39 Pusztai et al. SABCS 17
40 Grazie per l attenzione! VRossi@scamilloforlanini.rm.it
San Antonio Breast Cancer Symposium, December 5-9, San Antonio Breast Cancer Symposium, December 5-9, 2017
San Antonio Breast Cancer Symposium, December 5-9, 2017 Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationLo Studio Geparsepto. Alessandra Fabi Oncologia Medica 1
Lo Studio Geparsepto Alessandra Fabi Oncologia Medica 1 nab-paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto GBG 69): A Randomised, Phase III Trial
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationWhat to do after pcr in different subtypes?
What to do after pcr in different subtypes? Luca Moscetti Breast Unit Università degli Studi di Modena e Reggio Emilia Policlinico di Modena, Italy Aims of neoadjuvant therapy in breast cancer Primary
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar Paradigm shift? The Food and Drug Administration collaborative project P. Cortazar, Silver Spring, USA FDA Perspective: Moving from Adjuvant to Neoadjuvant Trials in
More informationLecture 5. Primary systemic therapy: clinical and biological endpoints
Lecture 5 Primary systemic therapy: clinical and biological endpoints Valentina Guarneri, M.D., Ph.D. Primary systemic therapy in breast cancer Firstly introduced d into clinical i l practice in 70s for
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer. Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center
Novel Preoperative Therapies for HER2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive Cancer Center Key Findings to Date in the Neoadjuvant Therapy of HER2+
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationDR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA
Recent Advances of Docetaxel in Management of Breast Cancer DR. BOMAN N. DHABHAR Consulting Oncologist Jaslok Hospital, Fortis Hospital Mulund, Wockhardt Hospital Mumbai & BND Onco Centre INDIA 1 ADJUVANT
More informationAssessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint
Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationPRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients
PRO: Pathologic Complete Response Does Predict Outcome for Early Stage Breast Cancer Patients Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute
More informationNeoadjuvant (Primary) Systemic Therapy
Diagnosis and Treatment of Patients with Primary and Metastatic reast Cancer Neoadjuvant (Primary) Systemic Therapy Neoadjuvant Systemic Therapy Versions 2002 2017: auerfeind / lohmer / Costa / Dall /
More informationAdjuvan Chemotherapy in Breast Cancer
Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationOverview of nab-paclitaxel in Breast Cancer
Overview of nab-paclitaxel in Breast Cancer William J. Gradishar MD FASCO FACP Betsy Bramsen Professor of Breast Oncology Robert H. Lurie Comprehensive Cancer Center Northwestern University Feinberg School
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationTNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017
TNBC: What s new Déjà vu All Over Again? Lucy R. Langer, MD MSHS Compass Oncology - SABCS 2016 Review February 21, 2017 The problem with TNBC 1. Generally more aggressive 2. ONLY chemotherapy 3. No other
More informationHormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?
Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London
More informationIn Honour of Dr. Neera Patel
In Honour of Dr. Neera Patel Residual Cancer Burden (RCB) vs Pathologic Complete Response (pcr) as an End-point W. Fraser Symmans, M.D. Professor of Pathology UT M.D. Anderson Cancer Center Pathologic
More informationFDA Briefing Document Oncologic Drugs Advisory Committee Meeting. September 12, sbla /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc.
/51 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting September 12, 2013 /51 Pertuzumab (PERJETA ) Applicant: Genentech, Inc. Disclaimer: The attached package contains background information
More informationADAPT. Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer
ADAPT Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer Therapieindikation gesteuert durch prognostische Information
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationTerapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari
Terapia sistemica neoadiuvante: in quali tumori? Quali risultati? Dott. Giacomo Pelizzari Neoadjuvant Treatment A window of opportunity Rational: Historically proposed to enable breast-conserving surgery
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationI SPY 2 TRIAL. How it Works April 9, 2013
I SPY 2 TRIAL How it Works April 9, 2013 1 The Challenge in Breast Cancer Breast Cancer is a common and serious disease Over 200,000 new cases of invasive breast cancer each year Over 40,000 women will
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationTreatment of Early Stage HER2-positive Breast Cancer (One size does not fit all)
Treatment of Early Stage HER2-positive Breast Cancer (One size does not fit all) 8 November 2014 Edward H. Romond, M.D. Professor of Medicine Lucille Parker Markey Cancer Center University of Kentucky
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationBreast : ASCO Abstracts for Review
Breast : ASCO 2011 Susana Campos, MD, MPH Dana Farber Cancer Institute Abstracts for Review Prevention Neoadjuvant Metastatic Brain mets LBA 504: Exemestane for primary prevention of breast cancer in postmenopausal
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationSystemic Therapy for Locally Advanced Breast Cancer
Systemic Therapy for Locally Advanced Breast Cancer Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology National University Cancer Institute, Singapore Clinical Care Senior Principal
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationThe Expert Thoughts. Alessandra Fabi Oncologia Medica 1
The Expert Thoughts Alessandra Fabi Oncologia Medica 1 My Thoughts Neoadjuvant: from the lessons of the history Adjuvant: Escalation and De-escalation Advanced and HER2+ : field for immunomodulation Brain
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationRigshospitalet. Danish Breast Cancer Cooperative Group DBCG. Neo-adjuverende medicinsk behandling. Bent Ejlertsen. 16 th ACTA ONCOLOGICA SYMPOSIUM
DBCG Neo-adjuverende medicinsk behandling Bent Ejlertsen 16 th ACTA ONCOLOGICA SYMPOSIUM Baggrund; neoadjuverende behandling Eneste mulighed hos patienter med inoperabel brystkræft. Af Bonadonna udvidet
More informationRole of chemotherapy in BRCA and Triple negative breast cancer. Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos
Role of chemotherapy in BRCA and Triple negative breast cancer Fernando Moreno Servicio de Oncología Médica Hospital Clinico San Carlos Association between TNBC & germline mutations in BRCA 1/2 TNBC is
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2018 HER2-positive Breast Cancer Adjuvant
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationA Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast
Original Research Article A Study to Evaluate the Effect of Neoadjuvant Chemotherapy on Hormonal and Her-2 Receptor Status in Carcinoma Breast E. Rajesh Goud 1, M. Muralidhar 2*, M. Srinivasulu 3 1Senior
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationAdjuvant Chemotherapy TNBC & HER2 Subtype
Adjuvant Chemotherapy TNBC & HER2 Subtype 2015.08.15 Gun Min Kim Yonsei Cancer Center Division of Medical Oncology Department of Internal Medicine Yonsei University College of Medicine gmkim77@yuhs.ac
More informationRole of Genomic Profiling in (Minimally) Node Positive Breast Cancer
Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More informationCURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!?
CURRENT CONTROVERSIES IN BREAST CANCER SURGERY Less or more!? I have no Disclosures Wolfgang Gatzemeier Breast Unit Milan, Italy 17th ESO-ESMO- EONS Masterclass in Clinical Oncology 24-29 MARCH 2018 Optimal
More information(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer)
(Neo)Adjuvant Chemotherapy and biological Agents (essentials in HER2 and TN early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Neoadjuvant
More informationNovel Preoperative Therapies for HER2-Positive Breast Cancer
Key Findings to Date in the Neoadjuvant Therapy of H2+ Breast Cancer Novel Preoperative Therapies for H2-Positive Breast Cancer Debu Tripathy, MD University of Southern California Norris Comprehensive
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationADAPT: Her 2+/ HR - S. Kümmel Brustzentrum Kliniken Essen-Mitte
American Society of Clinical Oncology Jun 2016 ADAPT: Her 2+/ HR - S. Kümmel Brustzentrum Kliniken Essen-Mitte American Society of Clinical Oncology Jun 2016 Final analysis of the WSG- ADAPT HER2+/HR-
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationAnthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial
Anthracyclines for Breast Cancer? Are Adjuvant Anthracyclines Dispensible? Needs to be Answered in a Large Prospective Trial Joanne L. Blum, MD, PhD Baylor-Sammons Cancer Dallas, TX Early Breast Cancer
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Dilemmas in Adjuvant Chemotherapy Is adjuvant chemotherapy effective in ER+
More informationChemotherapy Insights San Antonio Breast Cancer Symposium. SABCS 2012 Chemotherapy Insights. Thanks to colleagues who shared slides,
Chemotherapy Insights from the 2012 San Antonio Breast Cancer Symposium Kathy S. Albain, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Cardinal Bernardin Cancer Center
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationthat the best available evidence has not demonstrated that pcr can predict long-term outcomes in the neoadjuvant setting.
pcr in one arm of a randomized clinical trial comparing two neoadjuvant chemotherapies predicts for improved event-free or overall survival in that arm of the clinical trial. perc noted that the NeoALTTO
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationGiuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups
Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive
More informationExiste-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon
Existe-t-il un sous groupe à risque qui pourrait bénéficier d une modification de la durée de traitement par trastuzumab? X. Pivot CHRU De Besançon In 25 results of 4 Adjuvant Herceptin trials have definitively
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More informationChoosing between different hormonal therapies. Rudy Van den Broecke UZ Ghent
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent What is the golden standard in premenopausal hormonal sensitive early breast cancer? Ovarian Suppression alone 5 years Tamoxifen
More informationpan-canadian Oncology Drug Review Initial Clinical Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer April 30, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Pertuzumab (Perjeta) Neoadjuvant Breast Cancer April 30, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationPrognostic and Predictive Factors
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Prognostic and Predictive Factors Prognostic and Predictive Factors Version 2002: Thomssen / Harbeck Version 2003 2009: Costa
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationUpdate in the treatment of Her2- overexpressing breast cancers. Fabrice ANDRE Institut Gustave Roussy Villejuif, France
Update in the treatment of Her2- overexpressing breast cancers Fabrice ANDRE Institut Gustave Roussy Villejuif, France Questions Should tumors
More informationOPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER. Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx
OPTIMIZING NONANTHRACYLINES FOR EARLY BREAST CANCER Stephen E. Jones, M.D. US Oncology Research, McKesson Specialty Health The Woodlands, Tx ANTHRACYCLINES AND TAXANES ARE COMMONLY USED USED IN MOST REGIMENS
More informationSubtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015
Subtype-directed therapy of TNBC Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium Jeju Island, Korea, April 2015 Ruth M. O Regan, MD Visiting Professor and Division Chief
More informationASCO and San Antonio Updates
ASCO and San Antonio Updates 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive Cancer Center Breakthroughs
More informationJanet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario
Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationSystemic Therapy of HER2-positive Breast Cancer
Systemic Therapy of HER2-positive Breast Cancer Tanja Cufer, MD, PhD University Clinic Golnik, Medical Faculty Ljubljana, Slovenia ESO ESMO Masterclass, Belgrade 2017 Relative Risk HER2-positive Breast
More information